Stellate Multiform Amelanotic Choroidopathy (SMACH)

Stellate multiform amelanotic choroidopathy (SMACH) is a newly described change in the choroid (the vascular layer under your retina). Doctors see a star-shaped (“stellate”) choroidal lesion that looks yellow-orange and non-pigmented (“amelanotic”) when they examine the back of the eye. On scans, the lesion sits in the choroid and may sometimes create pockets of fluid under the retina (subretinal fluid, SRF). Many people have no symptoms, while others notice blurred or distorted central vision if fluid or outer-retina stress develops. Importantly, the lesion itself doesn’t behave like a cancer and has not been seen to grow in the largest series so far; vision usually remains fairly stable over long follow-up. Lippincott Journals

SMACH was first grouped under “serous maculopathy due to aspecific choroidopathy” in 2021. In 2023, a multi-center case series (18 eyes, average age ~28 years, ~9 years of follow-up) showed a consistent star-like (dendriform) pattern on en-face OCT and hypofluorescence on indocyanine green angiography (ICGA); because subretinal fluid wasn’t always present, the authors proposed the current name, which kept the SMACH abbreviation. A 2025 clinician-curated summary emphasizes the same points and notes that anti-VEGF injections and photodynamic therapy didn’t help in that series, and that the fluid can fluctuate spontaneously while the lesion size stays still. Lippincott JournalsEyeWiki

Stellate multiform amelanotic choroidopathy—shortened to SMACH—is a rare eye condition that affects the choroid, the vascular layer under the retina that feeds the light-sensing tissue. The words in the name describe what doctors see on imaging:

• Stellate / multiform means the lesion often looks star-shaped or branching, with “finger-like,” dendrite-type projections, and it can vary in outline from case to case.

• Amelanotic means the lesion lacks dark pigment, so it looks cream-to-yellow-orange rather than brown or black.

• Choroidopathy means the main problem is in the choroid, not primarily the retina or vitreous.

In the largest case series so far, SMACH usually involved one eye and showed a yellow-orange, dendriform (branching) choroidal lesion. About half of patients had subretinal fluid (SRF)—a pocket of clear fluid under the retina—while the rest never developed fluid during years of follow-up. On optical coherence tomography (OCT), doctors saw hyper-reflective, fibrous-like change within the inner choroid, and on OCT-angiography the choriocapillaris flow was preserved. Indocyanine-green angiography (ICGA) typically showed early and late hypofluorescence of the lesion. These features help doctors tell SMACH apart from look-alike diseases. PubMedResearchGate

Where the name came from. The entity was first described as “serous maculopathy due to aspecific choroidopathy” (also abbreviated SMACH) and later renamed to highlight the consistent stellate, amelanotic choroidal pattern, because not all patients actually had serous (fluid) maculopathy. PubMed+1

How it behaves. In reported series, new abnormal blood vessels (MNV) have not been a typical finding, lesion growth has not been seen, and SRF can fluctuate without treatment. Because the condition is newly described and case numbers are small, there is no single, proven treatment, and many patients are observed. A retrospective series suggested no benefit from anti-VEGF injections or photodynamic therapy (PDT), but a recent individual case report described successful PDT; taken together, management remains case-by-case and evidence is limited. COREResearchGateDirectory of Open Access JournalsEyeWiki

---

Types

These are pragmatic clinical categories used to describe what doctors see. They are not formal subtypes, but they help in day-to-day care.

1. SMACH with subretinal fluid (SRF-positive). The stellate choroidal lesion has overlying fluid on OCT, often with retinal pigment epithelium (RPE) changes. Symptoms (blurred or wavy vision) tend to be more noticeable when fluid is present. PubMed

2. SMACH without subretinal fluid (SRF-negative). The stellate lesion is present, but no fluid is detectable over long follow-up. Vision may be near normal, and the finding may be incidental. PubMed

3. Early-appearance SMACH. Lesion shows prominent dendriform, amelanotic pattern; RPE change may be subtle. ICGA hypofluorescence is often visible early and late. ResearchGate

4. Chronic-appearance SMACH. RPE alterations become more obvious over time; OCT still shows inner-choroid hyper-reflective strands with preserved choriocapillaris flow on OCTA. PubMed

5. Unilateral SMACH (the usual). Almost all reported cases involve one eye at presentation and during follow-up. PubMed

Causes” or contributors

Key point: As of today, the true cause of SMACH is unknown. Published reports describe its look and behavior but do not establish a proven mechanism. The items below are plausible contributors or contextual factors doctors consider by analogy with related choroidal conditions (e.g., central serous chorioretinopathy, uveitic choroidopathies). They are hypotheses to guide thinking and rule-outs, not confirmed causes of SMACH.

1. Idiopathic choroidal remodeling. The choroid may lay down fibrous-like tissue in a stellate pattern for reasons we do not yet understand. This matches OCT descriptions. PubMed

2. Micro-injury to choroidal stroma. Minor injury might trigger local scarring without pigment. (Inference from imaging appearance; not proven.) PubMed

3. Focal RPE stress. The RPE over the lesion can look altered; stressed RPE sometimes leaks fluid, explaining the on-off SRF in some patients. (Inference.) PubMed

4. Vascular signaling imbalance without flow loss. OCTA shows preserved choriocapillaris flow, suggesting signaling problems rather than clogged vessels. (Inference from OCTA findings.) PubMed

5. Immune “wake-up call.” Some choroidopathies are immune-mediated; a mild, localized immune response could remodel tissue without classic uveitis signs. (Analogy to other choroiditis; inference.) EyeWikiPMC

6. Hormonal or stress milieu. In other choroidal fluid disorders (like CSC), corticosteroids and stress can worsen leakage; clinicians sometimes screen for these, though this link is unproven in SMACH. (Analogy.) NatureAAO

7. Systemic steroid exposure. Because steroids alter choroidal permeability in CSC, doctors often ask about steroid use; this is screened, not established as causal in SMACH. (Analogy.) Nature

8. Sleep disturbance and sympathetic drive. Sleep apnea and stress hormones affect choroidal blood flow in CSC; clinicians might ask about sleep, though this is speculative for SMACH. (Analogy.) NCBI

9. Hypertension or vascular dysregulation. General vascular health affects choroid perfusion; high blood pressure could aggravate choroidal stress. (General inference.)

10. High myopia or axial eye shape. Eye shape changes can alter choroidal thickness; clinicians document refractive status to understand background risk. (General inference.)

11. Prior ocular surgery or trauma (remote). Any past event might remodel local tissue, creating a site that later looks stellate. (General inference.)

12. Low-grade, self-limited inflammation. A brief, mild inflammation could heal with stellate scarring without classic uveitis history. (General inference.)

13. Focal choroidal hyperpermeability. Even with normal OCTA flow, leakiness in deeper vessels could contribute to intermittent SRF, as seen in other macular fluid disorders. (Analogy.) Nature

14. Genetic predisposition to stromal scarring. Some people scar in distinctive patterns; this might influence the stellate geometry. (Speculative.)

15. Oxidative stress at the RPE-choroid interface. Oxidative stress can injure RPE and alter the outer retina. (General inference.)

16. Autoimmune tendency without systemic disease. People can have organ-limited autoimmunity that never declares systemically. (Inference.)

17. Infectious mimickers ruled out. Doctors often test for syphilis or TB because those can mimic choroiditis; being negative does not cause SMACH, but it clarifies that infection is not the cause. EyeWiki

18. Environmental triggers (unproven). Caffeine, nicotine, or stimulants can worsen choroidal leak in CSC; not proven in SMACH but sometimes discussed. (Analogy.) Retina Today

19. Pregnancy-related fluid sensitivity (by analogy). Pregnancy affects fluid balance and hormones; it modulates CSC risk, so clinicians note obstetric history; no data in SMACH yet. (Analogy.) NCBI

20. Truly idiopathic. The most honest “cause” today is “we don’t know yet,” and more cases and longitudinal imaging are needed. PubMed

---

Symptoms and day-to-day

Symptoms vary with location (usually macula) and presence of SRF. Some people are asymptomatic when no fluid is present.

1. Blurred central vision. The macula is the sharp seeing center; any fluid or tissue change there blurs fine detail. PubMed

2. Wavy or distorted lines (metamorphopsia). SRF lifts the retina like a tiny blister, so straight lines can look bent. PubMed

3. A small gray spot or smudge (central scotoma). A focal blind spot can appear where the lesion affects the photoreceptors. PubMed

4. Objects seem smaller (micropsia). When the retina is elevated, things can look shrunken in the affected eye.

5. Reduced contrast. Fine textures fade—e.g., print looks washed out, even if letters are still readable.

6. Color dulling. Colors may look less vivid, especially reds.

7. Difficulty with reading speed. Tracking small text is harder when central vision is disturbed.

8. Trouble in dim light. Minor central blur becomes more obvious in low light.

9. Glare sensitivity. Bright light can scatter on the fluid pocket or altered RPE and feel harsh.

10. Intermittent improvement or worsening. SRF can fluctuate, so vision may change day to day. CORE

11. Depth-perception mismatch. If only one eye is affected, the brain gets uneven input, making distances feel “off.”

12. Headache or eye strain. The effort to reconcile two different images can cause fatigue.

13. No pain or redness. SMACH is not a front-of-the-eye inflammation; the eye looks quiet.

14. Often only one eye is involved. The other eye can feel normal, delaying detection. PubMed

15. Sometimes no symptoms at all. When no SRF is present and the fovea is spared, the lesion can be an incidental imaging finding. PubMed

---

Diagnostic tests

Doctors combine examination and multimodal imaging to confirm SMACH and exclude mimics such as central serous chorioretinopathy (CSC), birdshot chorioretinopathy, choroidal nevi/melanoma, or inflammatory choroiditis.

A) Physical examination (at the slit lamp and in the clinic)

1. Best-corrected visual acuity (VA). Measures clarity of vision (letters on a chart). In SMACH it ranges from normal to reduced, depending on SRF and foveal involvement. PubMed

2. Pupil tests (afferent defect). Usually normal; helps rule out optic nerve disease.

3. Anterior-segment exam. Looks for cells, flare, keratic precipitates; SMACH usually shows no anterior uveitis, distinguishing it from many inflammatory disorders. EyeWiki

4. Dilated fundus exam. The doctor inspects the back of the eye and may see a yellow-orange, dendriform choroidal lesion with a quiet vitreous. PubMed

5. Intraocular pressure (IOP). Typically normal; high or low IOP would point to other problems.

B) Manual/bedside functional tests

6. Amsler grid. A checkered card to map wavy lines or blind spots; helpful for metamorphopsia tracking.

7. Near-vision/reading assessment. Detects small central defects that regular distance VA can miss.

8. Pinhole test. Differentiates refractive blur from retinal blur; SMACH blur won’t clear with pinhole.

9. Color vision plates. May show mild color desaturation if the macula is affected.

10. Contrast sensitivity chart. Often reveals functional loss before big VA changes.

C) Laboratory / pathological rule-outs (SMACH has no specific blood test)

11. Syphilis serology (e.g., treponemal tests). Excludes a treatable mimic of choroiditis. EyeWiki

12. TB testing (IGRA/QuantiFERON). Rules out tuberculous choroiditis, another mimic. EyeWiki

13. ACE/lysozyme and chest imaging when indicated. Looks for sarcoidosis if clinical suspicion arises. (Mimic rule-out.) EyeWiki

14. HLA-A29 typing (if birdshot suspected). Birdshot is a bilateral uveitis with cream-colored lesions and strong HLA-A29 association; typing helps differentiate it. EyeWikiNCBI

D) Electrodiagnostic tests (used selectively)

15. Full-field ERG. Assesses global retinal function; usually normal in focal macular conditions; used to rule out widespread photoreceptor disease.

16. Multifocal ERG (mfERG). Maps central retinal responses; can show reduced signals over the lesion/SRF area. (General retinal physiology principle.)

17. Visual evoked potential (VEP). Checks signal conduction to brain; typically normal unless there is optic pathway involvement; helps exclude optic neuropathy.

E) Imaging tests (the core of diagnosis)

18. Optical coherence tomography (OCT). High-resolution cross-sections show subretinal fluid (if present) and fibrous-like hyper-reflective changes in the inner choroid beneath altered RPE. This is the signature structural finding. PubMed

19. En face OCT. “Top-down” OCT view highlights the stellate, dendriform pattern—often the most striking clue. ResearchGate

20. OCT-angiography (OCTA). Shows preserved choriocapillaris flow despite the lesion, helping distinguish SMACH from ischemic choriocapillaris diseases. PubMed

21. Indocyanine green angiography (ICGA). Typically shows early and late hypofluorescence at the lesion—another key imaging hallmark. ResearchGate

22. Fundus autofluorescence (FAF). Maps RPE stress or loss over/around the lesion; can highlight chronic change. (Inferred from RPE alteration reports.) PubMed

23. Fluorescein angiography (FA). Helps rule out leaking neovascular membranes or vasculitis; SMACH usually lacks the neovascular leakage pattern. (From series noting no MNV.) CORE

24. Color fundus photography. Documents the cream-to-yellow-orange stellate lesion over time. PubMed

25. B-scan ultrasonography (if a mass is suspected). Not routinely needed in classic SMACH, but helpful when clinicians must exclude an amelanotic melanoma or nevus masquerader. PubMed

26. Comparative imaging of both eyes. Because SMACH is commonly unilateral, comparing sides helps confirm pattern and baseline. PubMed

Non-pharmacological treatments and supports

1. Watchful waiting with a plan: Many cases stay visually stable; structured monitoring catches change without overtreatment. Purpose: safety net. Mechanism: lets natural SRF fluctuation declare its course. EyeWiki

2. Scheduled imaging (OCT/en-face OCT): Baseline, then periodic; extra visits if symptoms change. Purpose: track SRF and outer retina. Mechanism: objective trend data. Lippincott Journals

3. Amsler grid at home: Check lines daily in each eye. Purpose: detect new distortion/scotoma quickly. Mechanism: early self-signal → faster care.

4. Lighting optimization for reading: Brighter, directed light reduces strain if contrast is affected. Mechanism: improves retinal signal-to-noise.

5. High-contrast reading materials & accessibility settings (bold fonts, larger text): Mechanism: compensates for reduced contrast sensitivity.

6. Near-task ergonomics: Increase working distance, use larger screens, enable screen zoom. Purpose/Mechanism: reduce foveal demand per character.

7. Magnifiers or electronic video magnification (CCTV, tablet apps): Mechanism: projects larger retinal image to bypass small scotomas.

8. Tinted filters only if photophobia bothers you: Purpose: comfort; Mechanism: reduces glare—no disease-modifying effect.

9. Monocular occlusion for bothersome binocular rivalry: Temporary patching/frosted tape for short tasks; Mechanism: eliminates perceptual conflict.

10. Driving safety counseling: Follow local rules; avoid night driving if contrast is poor; Mechanism: harm reduction.

11. Workplace accommodations: Extra monitor, larger fonts, flexible lighting; Mechanism: sustained visual comfort.

12. Eye-strain breaks (“20-20-20”): Every 20 minutes, look 20 feet away for 20 seconds; Mechanism: reduces accommodative fatigue (comfort measure).

13. Treat unrelated ocular surface dryness (artificial tears): Comfort only; Mechanism: sharper optics can improve perceived clarity.

14. General cardiovascular health (BP, lipids, glucose) with your PCP: Not SMACH-specific but protects retina broadly. Mechanism: reduces background vascular stress.

15. Avoid unnecessary systemic steroids unless essential: Steroids aren’t known to cause SMACH, but in other fluid disorders (CSCR) they can worsen SRF; prudence is reasonable. Mechanism: avoids steroid-related fluid retention pathways. NCBI

16. Psychological support / reassurance: Understanding that the lesion is not a tumor and often stable lowers anxiety. Mechanism: reduces stress-related visual hypervigilance. Lippincott Journals

17. Shared decision-making about any procedure (e.g., PDT): If proposed, insist on specific goals, time-bound trial, and clear stop criteria. Mechanism: prevents procedural drift without benefit. EyeWikiScienceDirect

18. Photography log (phone through the scope images, if provided) + symptom diary: Mechanism: correlates perceived change with OCT findings.

19. Protective eyewear for sports/trauma risk: General retinal safety.

20. Regular follow-up with a retina specialist familiar with SMACH: Ensures nuanced interpretation of evolving literature. Mechanism: evidence-aligned care.

Drug treatments

Key disclaimer: No medication has proven disease-modifying benefit for SMACH. Items below are either supportive, for complications, or extrapolated from other chorioretinal fluid disorders. Do not start or stop any medicine without your ophthalmologist.

1. No-treatment/observation (the default): Purpose: avoid ineffective or harmful therapy; Mechanism: respects natural fluctuation; Side effects: none. Evidence: largest series showed no benefit from anti-VEGF or PDT and stable lesion size. EyeWikiLippincott Journals

2. Acetazolamide (off-label): Sometimes tried in other SRF conditions to accelerate fluid resorption via RPE pump support. Typical dose in other eye conditions: 250–500 mg/day short term; Mechanism: carbonic anhydrase inhibition → RPE fluid transport; Side effects: tingling, fatigue, kidney stones, sulfa allergy. Evidence in SMACH: absent; consider only within specialist guidance.

3. Topical dorzolamide/brinzolamide (off-label): Same rationale as #2 but topical; Mechanism/side effects: local irritation/blur; SMACH evidence: none.

4. Eplerenone/spironolactone (off-label, CSCR analogue): Aimed at choroidal fluid pathways in chronic CSCR (evidence mixed); SMACH evidence: not established; Side effects: electrolyte changes, dizziness; dosing varies (eplerenone often 25–50 mg/day in CSCR studies). NCBIOphthalmology & Visual Sciences

5. Anti-VEGF injections (for complications only): Not helpful for the core SMACH lesion in the main series; could be considered only if true CNV is proven (rare/unreported in series). Dosing (other diseases): monthly induction then PRN; Risks: endophthalmitis (rare). EyeWiki

6. Short course oral NSAIDs for eye-strain headaches: Supportive only; Mechanism: analgesia; Risks: GI, renal; not disease-modifying.

7. Topical NSAIDs: Comfort measure in select patients (little role).

8. Antioxidant “AREDS2” formula: Not a SMACH treatment; sometimes used for general macular support (vit C 500 mg, vit E 400 IU, lutein 10 mg + zeaxanthin 2 mg, zinc 80 mg [or 25 mg as zinc oxide], copper 2 mg). Mechanism: oxidative stress buffering; Evidence: for AMD, not SMACH.

9. Vitamin D repletion (if deficient): General health, not disease-modifying; dose per blood test and PCP.

10. Any immunosuppressant/steroid: Not recommended for SMACH (non-inflammatory pattern, absence of ICGA hyperpermeability); use only if diagnosis shifts to a true inflammatory chorioretinopathy after thorough work-up. EyeWiki

Dietary “molecular” supplements

Nutrition supports overall retinal health but does not treat SMACH. Discuss supplements with your clinician, especially if you take anticoagulants or have kidney disease.

1. AREDS2 mix (see #8 above): antioxidant/zinc support for macula health (AMD evidence).

2. Lutein (10 mg) + zeaxanthin (2 mg) daily: macular pigment support.

3. Omega-3s (EPA/DHA 1–2 g/day): general anti-inflammatory milieu; may help dry eye comfort.

4. Vitamin D to normal range: systemic health.

5. B-complex (especially B12 if low): neuro-support; dose per labs.

6. CoQ10 (100–200 mg/day): mitochondrial support (general).

7. Alpha-lipoic acid (200–400 mg/day): antioxidant; monitor for GI upset.

8. Bilberry extract (per label): anthocyanins; modest contrast support reported in other contexts.

9. Curcumin (up to 1 g/day with piperine): systemic antioxidant; check drug interactions.

10. Magnesium (200–400 mg/day): neural/vascular tone; avoid if kidney disease.

Again, none of these have evidence in SMACH; they are optional adjuncts for general eye wellness.

Regenerative / stem-cell” drugs

There are no approved immune boosters, regenerative drugs, or stem-cell therapies for SMACH. Doses do not exist because these are not treatments for this condition today. Research in other eye diseases explores: RPE cell transplantation, photoreceptor progenitor cells, gene therapy for specific retinal dystrophies, neurotrophic factors, platelet-derived or exosome approaches, and bioengineered RPE patches—but these are experimental and not targeted to SMACH. If you see “stem cell” clinics advertising cures, avoid them and seek an academic retina opinion.

Surgeries

• There is no standard surgery for SMACH. The lesion is choroidal, non-neoplastic, and typically stable. Surgery is reserved for rare diagnostic dilemmas or unrelated complications:

1. Diagnostic vitrectomy/biopsy (exceptional): only if a tumor cannot be ruled out by imaging and expert review.

2. Subretinal fluid drainage: not typical; SRF usually fluctuates and resolves without surgery.

3. Photodynamic therapy (PDT): a procedure, not a surgery; in the main series it did not help, but isolated case reports exist—consider only in a trial-like, shared-decision framework. EyeWikiScienceDirect

4. Tumor-directed procedures: only if the diagnosis ultimately proves to be something else (e.g., choroidal melanoma/osteoma/hemangioma) after full work-up.

5. Retinal detachment surgery: not a SMACH feature; would be for a different problem if it ever occurred.

---

Prevention

We cannot prevent SMACH specifically because the cause is unknown, but you can protect overall retinal health and ensure early intervention if anything changes:

1. Keep scheduled retina follow-ups and report new distortion fast.

2. Photograph your Amsler grid changes to show your doctor.

3. Wear eye protection for sports/DIY.

4. Keep blood pressure, lipids, and glucose in target ranges.

5. Don’t start or stop steroids without medical advice. NCBI

6. Manage sleep, stress, and screen ergonomics to reduce strain.

7. Use good lighting and larger fonts to minimize foveal stress.

8. Treat dry eye for clearer optics.

9. Avoid tobacco; limit heavy alcohol.

10. Maintain a Mediterranean-style diet rich in leafy greens and oily fish.

When to see a doctor urgently

• Right away if you notice sudden new blur, wavy lines, a dark spot, flashes/floaters surge, or eye pain/redness.

• Promptly (days) if distortion or blur worsens or doesn’t settle.

• Routinely per your specialist’s plan (often every 3–6 months at first, then tailored), with earlier visits if your home Amsler changes.

What to eat / what to avoid

Eat more: 1) leafy greens (spinach, kale), 2) orange/yellow veg (lutein/zeaxanthin sources), 3) oily fish (salmon/sardines 2–3×/week), 4) berries/citrus (antioxidants), 5) nuts/legumes (healthy fats), 6) whole grains, 7) adequate hydration, 8) foods rich in zinc (pumpkin seeds), 9) foods rich in vitamin D (or supplement to normal levels), 10) balanced meals that support vascular health.

Limit: ultra-processed foods, excessive sugar, heavy alcohol, trans-fats, and tobacco—all of which harm overall ocular-vascular health. (These are general eye-health tips, not SMACH-specific treatments.)

FAQs

1. Is SMACH cancer? No. It mimics tumors visually but behaves non-neoplastically and doesn’t grow in reported series. Lippincott Journals

2. Will it spread to my other eye? Most reported cases are unilateral; the other eye is usually normal. Lippincott Journals

3. Will I go blind? That’s very unlikely. Vision tends to remain stable; symptoms track with SRF fluctuations. Lippincott Journals

4. Why is my OCT so important? It shows the inner-choroidal changes and any fluid with high precision—key to management. Lippincott Journals

5. Do I need injections (anti-VEGF)? Not for SMACH itself in current evidence; only if a true CNV develops (rare/unreported in the main series). EyeWiki

6. What about PDT laser? The largest series saw no benefit; a single case report suggested improvement—discuss risks/benefits carefully. EyeWikiScienceDirect

7. Are steroids helpful? No—SMACH isn’t an inflammatory disease pattern. EyeWiki

8. Will lifestyle changes cure it? No, but lighting, magnification, and healthy habits can improve comfort and function.

9. Is it inherited? No genetic pattern is known.

10. Is it caused by screens or phones? No evidence of that.

11. Can I exercise? Yes; if vision is asymmetric, be cautious with activities requiring precise depth perception.

12. What monitoring schedule is common? Often 3–6-monthly early on, then individualized; sooner if symptoms change.

13. Could this actually be something else? Your doctor rules out CSCR, Best disease, placoid chorioretinitis, and choroidal tumors using multimodal imaging. EyeWiki

14. Do supplements help? They don’t treat SMACH, but general eye-healthy nutrition is reasonable.

15. What’s the most important thing I can do? Keep follow-ups, check an Amsler grid, and seek care promptly for changes.

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: August 26, 2025.